Patent application number | Description | Published |
20090141707 | SYSTEMS AND METHODS FOR PROVIDING EMERGENCY SERVICE TRUST IN PACKET DATA NETWORKS - A method and apparatus for providing in a packet data telecommunication network serving one or more end terminals and/or Mobile Stations (MSs), a method for establishing, managing, modifying, and terminating an End-to-End (E2E) Emergency Service (ES) Chain-of-Trust (CoT) from an Access Serving Network (ASN) and Connectivity Service Network (CSN) to a PSAP, PSAP proxy, or PSAP (i.e. PSTN) gateway that results in the creation of a trust relationship amongst the components in the established ES CoT necessary to allow or validate the granting of any unauthenticated or unprovisioned ES network access and ES operation establishment, modification, and termination requests from amongst the components in an ES CoT to assist a particular terminal/MS or ES network component attempting to establish an ES session between the ES user agent of the terminal/MS and a serving PSAP. | 06-04-2009 |
20100199290 | SYSTEM AND METHOD FOR MULTIFUNCTION DEVICE ENUMERATION - Disclosed are systems and methods for controlling the enumeration of a multifunction peripheral device on a host computer. A multifunction peripheral device may include a generic and non-generic functional units connected to a host interface. The device may store in its non-volatile memory one or more drivers for the non-generic functional unit. The peripheral device may further include a controller for controlling the order in which the generic and non-generic functional units are exposed to and enumerated on the host system. The controller may include a switch operable to switch on and off the generic and non-generic functional units thereby controlling the order in which these units are exposed to and enumerated on the host system. | 08-05-2010 |
20100216524 | APPARATUS PROVIDING PLURAL WIRELESS TRANSCEIVERS WITHIN A DESIRED POWER BUDGET AND ASSOCIATED METHOD - The present invention provides an apparatus providing plural wireless transceivers within a desired power budget and associated methods. A plurality of wireless communication modules, each having a lower-power state and a higher-power state are provided, drawing power from a common source. Arbitration is performed to control which of the plurality of wireless communication modules are in the higher-power state, thereby controlling total power delivered by the power source to the plurality of wireless communication modules. | 08-26-2010 |
20110103384 | ROUTING DEVICE AND METHOD OF CONFIGURATION FOR NETWORK NAME RESOLUTION OF SAME - There is provided a routing device configured for operatively interconnecting a first digital data network (DDN) and a second DDN. The routing device comprises a first and second interface for operative connection with the respective first and second DDN and for transferring data packets associated with the first and second DDN. The routing device further comprises a processing system for processing the data packets and for transferring the data packets between the first interface and the second interface based upon address information encoded in the data packets. The processing system is configured with a routing device designation for identifying the routing device and a network address associated with the first DDN. Upon activation of the routing device, the processing system returns the network address in response to a network name resolution request for the routing device designation encoded in one or more first data packets characterized by one or more predetermined network protocols received from the first DDN. | 05-05-2011 |
20110199901 | METHOD AND APPARATUS FOR MANAGING COMMUNICATIONS IN A WIRELESS COMMUNICATION SYSTEM - The present technology provides a method and apparatus for managing communications in a wireless communication system. The method and apparatus evaluate one or more network traffic levels, each network traffic level associated with a respective network sector, and submit access-configuration messages in one or more network sectors when the evaluated network traffic level of a particular network sector has a predetermined relation to the traffic threshold for that particular network sector. The access-configuration messages are configured to shift one or more of wireless devices into one or more predetermined operational conditions. The present technology further provides corresponding wireless devices. | 08-18-2011 |
20110261891 | MANAGING COMMUNICATION OPERATIONS OF WIRELESS DEVICES - Management of communication operations of wireless devices is provided. A traffic-control parameter is generated, for example at a base station, indicative of desired aspects of communication operations of the wireless devices. The one or more traffic-control parameters may comprise a delay parameter, such as a maximum value for generating random backoff times, and/or a connection-time parameter, indicative of the maximum length of time a wireless device can hold a connection. A bit sequence indicative of the one or more traffic-control parameters is generated and communicated to the wireless devices. A wireless device determines the traffic-control parameter based on the communicated bit sequence and adapts its operation based thereon. | 10-27-2011 |
20120023257 | METHOD AND APPARATUS FOR NETWORK PORT AND NETWORK ADDRESS TRANSLATION - The present invention provides a method and apparatus for network port and network address translation. Several problems with limited addressability may occur when transmitting data packets between a terminal in a first network and a terminal in a second network that is outside the first network. Data forwarding rules are used to define if and how identifiers of data packets to be forwarded between the two networks correlate with each other. According to embodiments, a data forwarding rule includes a first identifier associated with the first network and a second identifier associated with the second network, wherein each identifier has two parts: a source address and source port number corresponding to a source network node, and a destination address and destination port number corresponding to a destination network node. | 01-26-2012 |
20120284385 | METHOD AND APPARATUS FOR MANAGEMENT OF NETWORK COMMUNICATIONS - A method and apparatus for maintaining a communication link through a NAT or other boundary device. Keep-alive messages (keep-alives) are transmitted and received by the boundary device to maintain the link therethrough. Address information of a keep-alive purports that keep-alive has traversed or is to traverse a predetermined portion of the communication link, such as a wireless “over the air” portion. However, the keep-alive is inhibited from traversing the predetermined portion. This may be accomplished by one or more of: spoofing the origin of the keep-alive such that it only appears to have traversed the predetermined portion; and causing the keep-alive to be discarded before traversal of the predetermined portion. Discard may be facilitated by configuration of the TTL field of the keep-alive or by use of a filtering device. | 11-08-2012 |
20130083717 | DYNAMIC ASSIGNMENT OF CELL BROADCAST MESSAGE IDENTIFIERS - A method and apparatus for broadcast communication from a broadcast entity to terminals of a wireless communication network. A request for broadcast access to the wireless communication network is received, the request comprising an indication of a predetermined feature. In response, a dynamic association is established between the feature and an identifier selected from a pool of currently unused identifiers. Messages are then received from the broadcast entity, the messages associated with the predetermined feature. The messages are then broadcast along with the identifier. Broadcasting may be via Cell Broadcast Service (CBS), with the CBS Message Identifier as said identifier. The terminals are configured to optionally use the identifier for selective message processing. Upon a predetermined expiry condition, the identifier may be returned to the pool for re-use. Information regarding the temporary association may be published to the terminals. | 04-04-2013 |
20130336111 | METHOD AND SYSTEM FOR WIRELESS COMMUNICATION WITH MACHINE-TO-MACHINE DEVICES - Approaches for managing machine-to-machine (M2M) wireless devices are disclosed. M2M devices may be managed using broadcast messages wirelessly transmitted from a server. M2M wireless devices may be configured to utilize service classes in order to implement network access policy control. Features include per-message or per-group security; randomized delays for acknowledgements and/or network access, optionally per group or network access rule; sequence numbers and/or retransmissions for QoS; pre-defined pathname shortcuts; network access rules based on time, congestion and network events; estimates of congestion at various nodes; spreading and/or maximum wait times; default or universal service classes; application data streams mapped to service classes; and offline triggering. | 12-19-2013 |
20140029493 | Wireless Communication Interworking Function - A method and apparatus facilitate data communication between a first device and a second device, such as an application server or Internet portal and a wireless terminal. A wireless link between devices supports communication via plural protocols, such as SMS and TCP/IP over GPRS. An interworking function (IWF) allows communication using native protocols, such as TCP/IP, but when appropriate (e.g. for small data transactions), translates messages to another protocol, such as SMS, for efficiency purposes. The IWF intercepts and responds to packets generated by the first device using the first protocol, as required. The IWF optionally selects a new protocol and generates and forwards packets, representative of the intercepted packets, to the second device. Protocol selection and/or turning the interworking function on/off can be performed dynamically based on efficiency criteria. The IWF may intercept packets before traversal of the wireless link, and may optionally reside in the wireless terminals. | 01-30-2014 |
20140295790 | METHOD AND SYSTEM FOR PROVIDING DIFFERENTIATED WIRELESS NETWORK ACCESS AND BILLING TO SUBSCRIBERS - The present technology provides a method and system for monetizing the usage of a certain “reserved service,” which comprises usage of certain reserved wireless operating modes, such as Ultra High Coverage Mode (UHCM), usage of one or more reserved Modulation and Coding Schemes (MCSs), or a combination thereof. In some embodiments the reserved MCSs may be employed solely when using the reserved operating mode. Similarly, the reserved operating mode may be defined at least in part by its usage of the reserved MCSs. | 10-02-2014 |
Patent application number | Description | Published |
20080233118 | Uses Of Antibody To M-Csf - Methods of using M-CSF antibodies to treat macrophage-associated diseases including atherosclerosis and HIV are provided. | 09-25-2008 |
20100092464 | M-CSF-Specific Monoclonal Antibody and Uses Thereof - M-CSF-specific RX1-based or RX-I derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in or remodeling in a subject afflicted with an osteoblastic or osteolytic disease. | 04-15-2010 |
20110091451 | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis - M-CSF antagonists are used to prepare compositions, including pharmaceutical compositions, for preventing or treating cancer metastasis and/or bone loss associated with cancer metastasis in a mammal. | 04-21-2011 |
20120045450 | METHOD FOR PREVENTING AND TREATING CANCER METASTASIS AND BONE LOSS ASSOCIATED WITH CANCER METASTASIS - M-CSF antagonists are used to prepare compositions, including pharmaceutical compositions, for preventing or treating cancer metastasis and/or bone loss associated with cancer metastasis in a mammal. | 02-23-2012 |
20140242071 | M-CSF SPECIFIC MONOCLONAL ANTIBODY AND USES THEREOF - M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease. | 08-28-2014 |
20150050280 | SOLUBLE HUMAN M-CSF RECEPTOR AND USES THEREOF - Methods of using M-CSF antibodies to treat macrophage-associated diseases including atherosclerosis and HIV are provided. | 02-19-2015 |
Patent application number | Description | Published |
20120183541 | HAIR GROWTH METHODS USING FGFR4 EXTRACELLULAR DOMAINS - The present invention relates to a method of promoting hair growth comprising administering a fibroblast growth factor receptor 4 (FGFR4) extracellular domain (ECD), including native FGFR4 ECDs, variants, fragments, and fusion molecules, to a subject in an amount sufficient to promote hair growth. | 07-19-2012 |
20130058928 | HAIR GROWTH METHODS USING FGFR3 EXTRACELLULAR DOMINS - The present invention relates to a method of promoting hair growth comprising administering a fibroblast growth factor receptor 3 (FGFR3) extracellular domain (ECD), including native FGFR3 ECDs, variants, fragments, and fusion molecules, to a subject in an amount sufficient to promote hair growth. | 03-07-2013 |
20140274898 | HAIR GROWTH METHODS USING FGFR3 EXTRACELLULAR DOMAINS - The present invention relates to a method of promoting hair growth comprising administering a fibroblast growth factor receptor 3 (FGFR3) extracellular domain (ECD), including native FGFR3 ECDs, variants, fragments, and fusion molecules, to a subject in an amount sufficient to promote hair growth. | 09-18-2014 |
Patent application number | Description | Published |
20090170776 | ANGIOGENICALLY EFFECTIVE UNIT DOSE OF FGF AND METHOD OF ADMINISTERING - The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose comprising 0.2 μg/kg to 36 μg/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. In another aspect, the present invention is directed to a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Typically, the angiogenically effective dose comprises 0.2 μg/kg to 36 μg/kg of an FGF of any one of SEQ ID NOS:1-3, 5, 8-10, or 12-14 or an angiogenically active fragment or mutein thereof. In yet another aspect, the present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of a human patient in need of treatment for coronary artery disease a safe and angiogenically effective dose of a recombinant FGF of any one of SEQ ID NOS:1-3, 5, 8-10, or 12-14, or an angiogenically active fragment or mutein thereof. | 07-02-2009 |
20120165245 | ANGIOGENICALLY EFFECTIVE UNIT DOSE OF FGF AND METHOD OF ADMINISTERING - The present invention provides a unit dose comprising 0.2 μg/kg to 36 μg/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of said patient a safe and angiogenically effective dose of a recombinant FGF of any of SEQ ID NOS:1-3, 5, 8-10, or 12-14, or an angiogenically active fragment or mutein thereof. | 06-28-2012 |
20140142038 | ANGIOGENICALLY EFFECTIVE UNIT DOSE OF FGF AND METHOD OF ADMINISTERING - The present invention provides a unit dose comprising 0.2 μg/kg to 36 μg/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of said patient a safe and angiogenically effective dose of a recombinant FGF of any of SEQ ID NOS:1-3, 5, 8-10, or 12-14, or an angiogenically active fragment or mutein thereof. | 05-22-2014 |
Patent application number | Description | Published |
20080200378 | KGF polypeptide compositions - Compositions comprising keratinocyte growth factor (KGF) polypeptides and methods of using the same are described. The KGF polypeptides of the present invention display enhanced bioactivity relative to full-length KGF | 08-21-2008 |
20090221504 | DOSE OF AN ANGIOGENIC FACTOR AND METHOD OF ADMINISTERING TO IMPROVE MYOCARDIAL BLOOD FLOW - The present invention has multiple aspects. In one aspect, the present invention is directed to a unit dose pharmaceutical composition comprising from about 5 ng/dose to less than 135,000 ng of an angiogenic agent, typically from 5 ng to 67,500 ng. Preferably, the angiogenic agent is FGF, more preferably it is basic FGF (FGF-2). In its second aspect, the present invention is directed to a method for inducing angiogenesis, or increasing myocardial perfusion or vascular density in a patient's heart, comprising administering directly into the myocardium in an area in need, as a single injection or a series of injections, a unit dose of an angiogenic agent. It is also within the scope of the present invention that a plurality of unit dose compositions be administered directly into the myocardium at a plurality of sites in need of angiogenesis. In another aspect, the present invention is directed to a method for treating a patient for coronary artery disease, comprising administering directly into the myocardium in an area of need of angiogenesis in said patient, a unit dose (i.e., from about 5 ng to less than 135,000 ng) of an angiogenic agent. In yet another aspect, the present invention is directed to a method for treating a patient for a myocardial infarction, comprising administering directly into the myocardium in an area in need of angiogenesis in said patient, a unit dose (i.e., from about 5 ng to less than 135,000 ng) of an angiogenic agent. | 09-03-2009 |